Coherus Biosciences appoints Charles Newton to Board of Directors

Coherus Oncology, Inc.

Charles Newton appointed as Class I director effective May 4, 2022, term expiring at 2024 annual meeting.
Newton also appointed to audit committee; is CFO of Lyell Immunopharma, a Nasdaq-listed biotech.
He receives $50,000 annual cash retainer and option to purchase 54,000 shares vesting over 3 years.
Newton previously co-headed healthcare investment banking at BofA Securities and Credit Suisse.
No material transactions requiring disclosure under Item 404(a) identified.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Charles Newton

Class I director

CHRS · Coherus Oncology, Inc.

Effective: 2022-05-04
Filed: May 10, 2022, 7:59 PM ET

On May 4, 2022, upon the recommendation of its Nominating and Corporate Governance Committee (the “Nominating Committee”), a vacancy on the Board of Directors (the “Board”) of Coherus BioSciences, Inc. (the “Company”) was filled with the appointment of Charles Newton.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Charles Newton was appointed as Class I director at Coherus Oncology, Inc..

Action: appointed
Role: Class I director

Exact text from the filing

On May 4, 2022, upon the recommendation of its Nominating and Corporate Governance Committee (the “Nominating Committee”), a vacancy on the Board of Directors (the “Board”) of Coherus BioSciences, Inc. (the “Company”) was filled with the appointment of Charles Newton.

View on SEC.gov

Coherus Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-146410

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.